Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference
February 02, 2023 08:00 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
December 20, 2022 09:21 ET
|
Satsuma Pharmaceuticals
Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating robust and sustained antimigraine effects on...
Satsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 23, 2022 13:59 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine
November 14, 2022 07:00 ET
|
Satsuma Pharmaceuticals
STS101 was not statistically superior to placebo at two hours post-administration on the co-primary endpoints of freedom from pain and most bothersome symptom STS101 showed superiority (p<0.001)...
Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 03, 2022 16:05 ET
|
Satsuma Pharmaceuticals
- On track to report topline results from STS101 SUMMIT Phase 3 efficacy trial in November 2022; NDA submission planned in Q1 2023 - - $64.4 million in cash, cash equivalents and marketable...
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
September 20, 2022 08:30 ET
|
Satsuma Pharmaceuticals
STS101 demonstrated a favorable safety and tolerability profile, consistent with clinical experience to dateOver 8,000 migraine attacks treated with more than 10,000 doses of STS101; of which, over...
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:02 ET
|
Satsuma Pharmaceuticals
South San Francisco, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program
August 09, 2022 16:05 ET
|
Satsuma Pharmaceuticals
- Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more than 1,400 subjects - - On track to announce SUMMIT trial topline results in Q4 2022 - - Completed...
Satsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
August 02, 2022 08:00 ET
|
Satsuma Pharmaceuticals
- More than 1,400 subjects randomized -- Satsuma expects to announce topline SUMMIT trial results in Q4 2022 - SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Satsuma...
Satsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society’s 64th Annual Scientific Meeting
June 09, 2022 07:00 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...